FDA Approves Drug Treatment for Overactive Bladder 09 nov 2008--The FDA has approved Toviaz (fesoterodine), an anticholinergic agent, to treat overactive bladder in adults. The drug relaxes smooth muscle in the bladder, thereby reducing urinary frequency, urgency, and incontinence. Available doses are 4 and 8 mg daily.
Contraindications include severely reduced kidney function, urinary or gastric retention, uncontrolled narrow-angle glaucoma, severe liver impairment, and use of medications (e.g., ketoconazole) that block fesoterodine metabolism. The FDA also recommends caution in prescribing fesoterodine for patients with decreased gastric motility.
LINK(S):
FDA announcement (Free)
09 nov 2008--The FDA has approved Toviaz (fesoterodine), an anticholinergic agent, to treat overactive bladder in adults. The drug relaxes smooth muscle in the bladder, thereby reducing urinary frequency, urgency, and incontinence. Available doses are 4 and 8 mg daily.
Contraindications include severely reduced kidney function, urinary or gastric retention, uncontrolled narrow-angle glaucoma, severe liver impairment, and use of medications (e.g., ketoconazole) that block fesoterodine metabolism. The FDA also recommends caution in prescribing fesoterodine for patients with decreased gastric motility.
LINK(S):
FDA announcement (Free)